Although artificial intelligence may seem like the great equalizer to humanity’s flawed motivational and cognitive biases, the truth is, even the most advanced AI technologies have biases including race, gender, socioeconomic status, and political identifiers.
If you are not happy with the results below please do another search
50 search results for:
Rare disease biotech BioMarin Pharmaceuticals Inc. announced Friday it was shedding around 4% of its global workforce, or around 120 jobs, in an effort to improve its operational efficiency.
Amgen opened a new research and development site in San Francisco Bay, which will be used to discover new therapeutics for cancer, inflammatory disease and cardiometabolic disorders, the company announced Thursday.
Allogene Therapeutics is launching what it calls the first pivotal Phase II trial of an allogeneic CAR T product in the industry.
Canada on Friday authorized updated COVID-19 booster shots from Pfizer Inc. and its partner BioNTech SE that target the Omicron BA.4 and BA.5 subvariants, according to the government’s website.
As the economy ebbs and flows, pharma and biotech companies alike are feeling the pressure to cut costs. From rapid inflation to the ever-changing regulatory landscape, many are looking for ways to reduce their burn rate.
Indonesia is in talks with several African countries, including Nigeria, to export and donate its homemade COVID-19 vaccine, its developer said on Friday, after becoming the first country in Southeast Asia to approve a domestically developed COVID shot.
A rebound of COVID-19 symptoms in some patients after taking Pfizer’s antiviral Paxlovid may be related to a robust immune response rather than a weak one, U.S. government researchers reported on Thursday.
The Nasdaq-listed company and Australia’s Victoria state said they signed a partnership to create a centre, which would run clinical research of experimental messenger ribonucleic acid, or mRNA, vaccines and therapies with the aim of attracting experts from around the world.
The alliance will combine this technology with Boehringer’s research and development expertise to develop a first-in-class treatment for patients with eye diseases, Surrozen announced.